Metformin has been found to inhibit the immune exhaustion of tumor-infiltrating CD8+ lymphocytes in multiple types of established cancers in mice, suggesting that it may be useful in reversing the immunosuppressive and CD8+ T-cell-exhausted tumor microenvironment in HCC patients. Here, CD8A is linked to cancer.